Salute e Benessere

Phase I Study Results for Qilu Pharmaceutical's Iparomlimab (QL1604) Now…

I. Study Background and Objectives I. Study Background and Objectives This study was an open-label Phase I clinical trial of QL1604 in patients with advanced or metastatic solid tumors. The primary objective of the study was to evaluate the safety and tolerability of QL1604 and to determine the recommended dosage for future clinical trials. II. Study Design and Patient Allocation The study consisted of dose escalation and dose expansion phases. BetweenMay 29, 2019andJuly 24,...
PR Newswire
06/11/2023

Daily Products Market to Reach 3.3 trillion, Globally, by 2032 at 8.2% CAGR…

Request The Sample PDF Of This Report: https://www.alliedmarketresearch.com/request-sample/189701 Request The Sample PDF Of This Report: https://www.alliedmarketresearch.com/request-sample/189701 Prime determinants of growth The daily products market is witnessing substantial expansion, driven by a host of industry trends and growth drivers. The advent of e-commerce and digitalization has revolutionized the way consumers access a broad spectrum of everyday essentials. These...
PR Newswire
06/11/2023

AliveDx receives IVDR Certification of its Manufacturing Sites in Switzerland…

The certification underscores our commitment to delivering high-quality solutions to healthcare professionals and patients across our businesses: Alba –– transfusion portfolio –– and MosaiQ® –– multiplexing and multimodality automated clinical diagnostics solution. The certification underscores our commitment to delivering high-quality solutions to healthcare professionals and patients across our businesses: Alba –– transfusion portfolio –– and MosaiQ ®–– multiplexing and multimodality...
PR Newswire
06/11/2023

'Listen to your patients for early identification of Peripheral Neuropathy' say…

Aalok Agrawal, Senior Vice-President, P&G Health (AMA) said, "As a partner to International Diabetes Federation (IDF), P&G Health is committed to continued efforts to raise awareness on Diabetes and its associated complications including PN and Vitamin B Deficiency. Our '#KNOWTHESIGNS Scientific Forum saw a multidisciplinary panel of experts come together to share clinical recommendations on diagnoses and management of PN in Diabetes and Pre-diabetes, impact of Vitamin B Deficiency…
PR Newswire
06/11/2023

TFS HealthScience Becomes First CRO to Adopt Medidata Detect, Improving Data…

"In spearheading our adoption of Medidata Detect, we're not only reinforcing our commitment to data quality and patient safety, but we're also embracing a pivotal enhancement to our existing technology stack," said Michael Mendoza, TFS Executive Director of eClinical Technology and Biometrics. "Our partnership with Medidata now extends beyond the realms of Rave® EDC, CTMS, and eTMF, illustrating a significant step in our long-term strategy to advance clinical trial efficiency…
PR Newswire
06/11/2023

XNK Therapeutics announces poster presentations at the 38th Annual Meeting of…

The second poster, titled Feeder-free Expansion of Autologous Cytotoxic NK Cells for Acute Myeloid Leukemia Treatment, describes the successful expansion and activation of autologous NK cells from PBMCs of diverse cohorts of patients with Acute Myeloid Leukemia (AML). The second poster, titledFeeder-free Expansion of Autologous Cytotoxic NK Cells for Acute Myeloid Leukemia Treatment, describes the successful expansion and activation of autologous NK cells from PBMCs of diverse cohorts of...
PR Newswire
06/11/2023

Medicover AB: Issue and repurchase of class C shares for incentive program

Nordea Bank Abp will subscribe for all issued class C shares at a subscription price of EUR 0.2 per share. All such 1,600,000 issued class C shares will be repurchased by Medicover AB (publ) at a purchase price of EUR 0.2 per share. Following the share issue, the share capital will increase by EUR 320,000. The class C shares do not entitle to dividends and each share entitles to 1/10 voting right. Nordea Bank Abp will subscribe for all issued class C shares at a subscription price of EUR 0...
PR Newswire
06/11/2023

VALNEVA Declaration of shares and voting rights: October 31, 2023

VALNEVADeclaration of shares and voting rightsOctober 31, 2023__________________________________________________________________________________________Company name: VALNEVA Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France) Regulated market of Euronext Paris - Compartment B Declaration date: November 6, 2023 Number of sharescomposing the share capital of ValnevaTotal number of voting rights including suspended voting rights* Description of the...
Nasdaq GlobeNewswire
06/11/2023

Notice of AGM

DXS INTERNATIONAL PLC Notice of 2023 Annual General MeetingThe Board of DXS International plc (the “Company”), the AQSE Growth Market quoted clinical decision support developer and supplier of clinical decision support systems, confirms that its Annual General Meeting is scheduled to take place on Thursday 30th November 2023 at Noon at the Pavilion Café, Tanshire Park, Shackleford Road, Elstead, Surrey GU8 6LB.For further information in relation to the AGM, shareholders should refer to...
Nasdaq GlobeNewswire
06/11/2023

Mendus presents updated ALISON clinical trial data for vididencel in ovarian…

Press Release Stockholm, Sweden, November 6, 2023Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced the publication of updated clinical data from the ongoing ALISON Phase 1 trial with the company's lead program vididencel at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting, the largest conference for cancer immunotherapy. The data demonstrate the boosting of broad immune responses...
Nasdaq GlobeNewswire
06/11/2023

NANOBIOTIX Announces the Availability of a Prospectus in Connection with Capital…

PARIS and CAMBRIDGE, Mass., Nov.06, 2023(GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “ Nanobiotix ” or the “ Company ”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announces the availability of the listing prospectus approved by the French Financial Markets Authority ( Autorité des Marchés Financiers– the “AMF”) under number 23-461, on November 3, 2023, in the context...
Nasdaq GlobeNewswire
06/11/2023

BerGenBio Announces Data from Biomarker Analyses in 2L NSCLC

BERGEN, Norway, Nov. 6, 2023 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced that a poster presentation detailing additional data from a Phase II trial of bemcentinib in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in second line Non-Small Cell Lung Cancer (NSCLC) patients was presented on November 4th at the 2023 Society of Immunotherapy of…
PR Newswire
06/11/2023

MDxHealth Announces the Approval by its Shareholders of the Proposed Transition…

NEWS RELEASE – REGULATED INFORMATION INSIDE INFORMATION NOVEMBER 6, 2023, 1:00 AM ET / 7:00 CET MDxHealth Announces the Approval by its Shareholders of the Proposed Transition to a Sole Listing of Shares on Nasdaq, and Details of the Share ConsolidationIRVINE, CA, and HERSTAL, BELGIUM– November 6, 2023 – MDxHealth SA (NASDAQ/Euronext Brussels: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announces that the...
Nasdaq GlobeNewswire
06/11/2023

MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody®…

MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody ®sonelokimab in active psoriatic arthritisFirst placebo-controlled randomized trial in active psoriatic arthritis (PsA) using a Nanobody ®to report positive topline results in support of potential best-in-class profilePrimary endpoint ACR50 met with up to 47% (p<0.01 versus placebo) of patients on sonelokimab achieving ACR50 as early as week 12All key secondary endpoints met including up to 77%...
Nasdaq GlobeNewswire
05/11/2023

New Phase 3 data with aprocitentan for patients with resistant hypertension has…

Allschwil, Switzerland – November 3, 2023Idorsia Ltd (SIX: IDIA) announced today that further data for aprocitentan, Idorsia's investigational dual endothelin receptor antagonist for the treatment of patients with resistant hypertension, were presented as an oral presentation entitled “ Effects of aprocitentan on blood pressure lowering and proteinuria in patients with chronic kidney disease and resistant hypertension ” by George Bakris, MD, at the American Society of Nephrology (ASN)...
Nasdaq GlobeNewswire
03/11/2023

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority) PARIS, Nov.03, 2023(GLOBE NEWSWIRE) -- Listing market: Euronext GrowthISIN code: FR0010425595DateTotal number of shares in the capitalTotal number of voting rights 10/31/202355,583,76861,519,396 For further information on Cellectis, please contact: Media contact: Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93, media@cellectis...
Nasdaq GlobeNewswire
03/11/2023

Innocan Pharma Announces Promising LPT-CBD Safety Indications -Implications from…

Animals were injected every several weeks with LPT-CBD over a period of 6 months, and showed: Animals were injected every several weeks with LPT-CBD over a period of 6 months, and showed: Based on these findings, the Innocan research team, led by Prof. Chezy Barenholz, assumes that LPT-CBD can be safely used for long-term therapy. LPT-CBD was initially designed for the treatment of chronic diseases that require a continuous drug administration and therapeutic effect. These data represent an...
PR Newswire
03/11/2023

Information on the Total Number of Voting Rights (Denominator) following…

Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 2 convertible bonds in Oxurion resulting in a EUR 50,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion.Leuven, BELGIUM, Boston, MA, US – November 3, 2023 – 08.00 PM CET– In...
Nasdaq GlobeNewswire
03/11/2023

At NECCI PR Roundtable 2023, Nkechi Ali-Balogun links fight against illicit…

Regrettably, she added the dark shadow of illicit trade threatens the very core of the industry's noble mission, jeopardizing public health and eroding the trust fundamental to the patient industry relationship. Regrettably, she added the dark shadow of illicit trade threatens the very core of the industry's noble mission, jeopardizing public health and eroding the trust fundamental to the patient industry relationship. Specifically, Nkechi noted communication, as a powerful tool, plays a...
PR Newswire
03/11/2023

Oncolytics Biotech® and SOLTI Present Further Positive Pelareorep Translational…

Thomas Heineman, M.D., Ph.D., Chief Medical Officer at Oncolytics, commented, "Previously published analyses from AWARE-1 patient samples showed that in the first three days after dosing, pelareorep upregulated tumor PD-L1 expression in the tumors, induced the generation and expansion of T cell clones, and promoted the tumor infiltration of CD8+ T cells. It also led to an increase in the CelTIL score in most patients, which is a measure of tumor cellularity and immune infiltration that…
PR Newswire
03/11/2023

Telesis Bio Announces Commercial Release of Cell-free Amplification Kit for…

New Kit offers BioXp automation workflow from candidate sequence to amplified DNA in days BioXp® De novo Cloning and Amplification kit on the BioXp 3250 and BioXp 9600 systems. This cell-free DNA amplification kit provides an efficient automated solution for building and amplifying DNA constructs to transfection-scale quantities in researchers' labs by skipping tedious bacterial scale-up and eliminating unpredictable service provider delivery times. The new kit will provide a robust and...
Nasdaq GlobeNewswire
03/11/2023

CDR-Life Presents Findings from Two Studies in Preparation of Phase 1 Trial with…

Therapeutic potential of CDR404, as a first-of-its-kind precision immunotherapy for HLA-A*02:01+ patients with MAGE-A4+ squamous non-small cell lung carcinoma (SQ-NSCLC) Development of a Quantitative Systems Pharmacology (QSP) model to facilitate discovery of safe and efficacious doses for upcoming Phase 1 trial ZÜRICH, Switzerland, Nov.03, 2023(GLOBE NEWSWIRE) --CDR-Life Inc., in the run-up to initiation of its first Phase 1 clinical trial, presented two posters for CDR404, a...
Nasdaq GlobeNewswire
03/11/2023

Medical Alert System/Personal Emergency Response System Market size worth $ 12.9…

Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=24881 Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=24881 Browse in-depth TOCon" Medical Alert System/Personal Emergency Response System Market " 202 - Pages 126 – Tables 37 – Figures Revolutionizing Elderly Care: Unveiling the Future of Medical Alert System/Personal Emergency Response System Market In a groundbreaking exploration of the...
PR Newswire
03/11/2023

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives…

Bagsværd, Denmark, 3 November 2023— This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company's board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company's board members, executives and...
Nasdaq GlobeNewswire
03/11/2023
Altri  Comunicati